AG-490 (Tyrphostin B42): Precision JAK2/EGFR Inhibitor for Signal Transduction Research

Executive Summary: AG-490 (Tyrphostin B42) is a highly selective tyrosine kinase inhibitor targeting JAK2 (IC₅₀ ≈ 10 μM), EGFR (IC₅₀ ≈ 0.1 μM), and ErbB2 (IC₅₀ ≈ 13.5 μM), with proven efficacy in modulating the JAK-STAT and MAPK signaling pathways in cancer and immune cells (Zhang et al., 2025; APExBIO). It is instrumental for suppressing hyperactive JAK2 in acute lymphoblastic leukemia (ALL) models and inhibiting IL-2-induced T cell proliferation (see also). AG-490 blocks STAT3 activation in mycosis fungoides-derived T cells and disrupts cytokine-driven immune polarization, supporting its use in immunopathological and oncology research. The compound demonstrates high solubility in DMSO (≥14.7 mg/mL) and ethanol (≥4.73 mg/mL), but is insoluble in water, and requires storage at -20°C. AG-490 is supplied by APExBIO at >99.5% purity for research use only.

Biological Rationale

Signal transduction pathways such as JAK-STAT and MAPK are central to cellular proliferation, differentiation, and immune regulation. Dysregulation of these pathways is a hallmark of oncogenesis and immunopathological disorders (Zhang et al., 2025). JAK2 mutations are frequently implicated in hematologic malignancies, while EGFR and ErbB2 overactivation drive tumorigenesis in multiple solid cancers. Pharmacological inhibition of these kinases enables mechanistic studies and therapeutic hypothesis testing in preclinical models. AG-490, as a member of the tyrphostin family, was developed to provide selective, reversible inhibition of these kinases (APExBIO).

Mechanism of Action of AG-490 (Tyrphostin B42)

AG-490 competitively inhibits the ATP-binding sites of JAK2, EGFR, and ErbB2, thus blocking phosphorylation events required for downstream signaling. In JAK2-expressing cells, AG-490 suppresses cytokine-induced activation, leading to reduced phosphorylation of STAT family transcription factors (e.g., STAT1, STAT3, STAT5a/b) (Zhang et al., 2025). In IL-2-dependent T cells, AG-490 inhibits IL-2-induced proliferation and STAT5 phosphorylation, decreasing DNA-binding activity of STAT1, STAT3, and STAT5. In mycosis fungoides T cells, AG-490 blocks STAT3 activation. It also targets JAK3 and disrupts MAPK signaling in select cell models (ErbB2.com).

Evidence & Benchmarks

• AG-490 inhibits JAK2 kinase activity with an IC₅₀ of ~10 μM in cell-free enzyme assays (APExBIO).
• AG-490 blocks EGFR kinase activity at an IC₅₀ of ~0.1 μM in biochemical assays (APExBIO).
• AG-490 suppresses JAK2 signaling and M2 macrophage polarization in exosome-treated THP-1 macrophages, demonstrating direct pathway inhibition (Zhang et al., 2025).
• AG-490 reduces STAT5a/b phosphorylation and DNA binding in IL-2-dependent T cell lines, inhibiting proliferation (MK-2206).
• AG-490 blocks STAT3 activation in mycosis fungoides-derived T cells, disrupting oncogenic signaling (ErbB2.com).
• AG-490 is insoluble in water, soluble in DMSO (≥14.7 mg/mL), and ethanol (≥4.73 mg/mL with gentle warming/sonication) (APExBIO).

Applications, Limits & Misconceptions

AG-490 is used primarily in cancer biology, immunopathological state suppression, and signal transduction research. It is a standard reagent for dissecting JAK-STAT and MAPK pathways in vitro. The compound enables studies of exosome-driven macrophage polarization, especially in hepatocellular carcinoma models investigating SNORD52/JAK2/STAT6 axis activation (Zhang et al., 2025). It also facilitates research into IL-2-induced T cell proliferation and kinase-driven malignancies.

For further insight into the breadth of AG-490 applications, see this ErbB2.com article, which details AG-490's roles in tumor immunology and signal modulation, whereas this article adds specific evidence for exosomal pathway inhibition. For advanced protocols and troubleshooting, refer to the MK-2206.com guide; here, the focus is on quantitative benchmarks and mechanistic specificity.

Common Pitfalls or Misconceptions

• AG-490 does not directly inhibit kinases outside the JAK/EGFR/ErbB2 family at relevant concentrations; broad-spectrum use is not supported.
• AG-490 is not recommended for use in vivo due to poor pharmacokinetic properties and low solubility in aqueous solutions.
• Long-term solution storage (>1 week at -20°C) is discouraged due to compound instability (APExBIO).
• AG-490 should not be used as a substitute for genetic loss-of-function experiments (e.g., CRISPR or shRNA knockdown) due to possible off-target effects at high concentrations.
• Results obtained in cell lines may not translate directly to primary cells or in vivo systems without further validation.

Workflow Integration & Parameters

AG-490 is supplied as a solid by APExBIO (SKU: A4139; purity >99.5%). Prepare stock solutions in DMSO (≥14.7 mg/mL) or ethanol (≥4.73 mg/mL) with gentle warming or sonication. Use freshly prepared solutions, avoiding repeated freeze-thaw cycles. Typical in vitro final concentrations range from 1 μM (for EGFR inhibition) up to 20 μM (for JAK2/ErbB2), depending on cell type and assay design. Incubation periods generally span 1–48 hours at 37°C in standard cell culture media. Negative controls should include vehicle-only (DMSO or ethanol) at matched concentrations. Store solid AG-490 at -20°C in a desiccated environment; avoid exposure to light and moisture. For further details on experimental set-up and interpretation, see the AG-490 (Tyrphostin B42) product page.

Conclusion & Outlook

AG-490 (Tyrphostin B42) is a validated, high-purity JAK2/EGFR inhibitor, essential for dissecting the molecular basis of signal transduction in cancer and immune cell research. Its documented efficacy in blocking JAK-STAT signaling, modulating immune polarization, and inhibiting cytokine-driven proliferation renders it a preferred tool for mechanistic investigation. However, its use should be limited to in vitro and ex vivo systems due to solubility and stability constraints. As research expands into exosome-mediated signaling and tumor microenvironment modulation, AG-490 remains a foundational chemical probe for pathway-specific intervention (Zhang et al., 2025).